BioSpace News Archive

Multi-regional strategic initiatives agreement designed to improve efficiency in care delivery, reduce cost, and enhance experience for health care consumers and providers.

Lannett Company, Inc. announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® of Respirent Pharmaceuticals Co. Ltd.

Abeona Therapeutics Inc., a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, announced that they have entered into license and inventory purchase agreements for ABO-202, an adeno-associated virus gene therapy for CLN1 disease.

Brain Scientific Inc., a neurology-focused medical device and software company, announced an expansion of their facilities via a headquarter relocation to Bohemia, New York in central Long Island.

Fulgent Genetics, Inc., a technology company providing comprehensive testing solutions through its scalable technology platform, announced that it has opened “Fulgent Houston,” a CLIA- certified laboratory in Houston, Texas.

Companion diagnostic will leverage the Oncomine Precision Assay to identify non-small cell lung cancer patients who may benefit from pyrotinib

Alkermes plc announced the publication of results from the phase 3 ENLIGHTEN-2 clinical trial of ALKS 3831 in the peer-reviewed publication, American Journal of Psychiatry.

Nemaura Medical Inc. provided a business update and on August 14, 2020 released financial results for the quarter ended June 30, 2020.

Phase 1/2a trial of Ampligen in combination with interferon alfa-2b in cancer patients with COVID-19 is on track for enrollment

CytoSorbents Corporation has entered into separate agreements with InvoSurg Inc. and Surgical Partners to commercialize CytoSorb® under its FDA Emergency Use Authorization in adult, critically-ill, COVID-19 patients with imminent or confirmed respiratory failure.